Validação de um Algoritmo de Decisão no Tratamento da Tuberculose em Crianças Infectadas pelo HIV
TB-Speed HIV is a prospective multicentre management study evaluating the safety and feasibility of the recently proposed PAANTHER TB treatment decision algorithm for HIV-infected children with presumptive TB. It will be conducted in four countries with high and very high TB (Tuberculosis) incidence (Côte d'Ivoire, Uganda, Mozambique, and Zambia) which have not participated in the study that developed the PAANTHER algorithm.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The ANRS 12229 PAANTHER 01 (Pediatric Asian African Network for Tuberculosis and HIV Research) study, which enrolled 438 HIV-infected children of median age 7.3 (IQR: 3.3 - 9.7) years with presumptive TB in four countries (Burkina Faso, Cameroon, Cambodia, Vietnam) from 2011 to 2014, aimed at developing a diagnostic prediction score and algorithm for TB treatment decision in HIV-infected children. This was the first study developing a TB diagnostic score exclusively in HIV-infected children, using methods recommended for diagnostic prediction models. Based on microbiological, clinical and radiological features, the best scoring system obtained had a sensitivity of 88.6% and specificity of 61.2% when Xpert MTB/RIF was included in the algorithm. The investigators showed previously that mortality is high in children with both confirmed and unconfirmed TB and that initiation of anti-TB treatment, that occurred at a median time of 7 (IQR: 5 - 11) days in the study, led to delayed ART initiation, which is associated to significantly increased mortality. The score, based on easily collected clinical features, chest radiographic features, Xpert MTB/RIF results, and abdominal ultrasonography, could enable same-day TB treatment decision. Abdominal ultrasonography has shown promise for the diagnosis of TB in both HIV-infected adults and children. In the PAANTHER study, it detected abdominal lymphadenopathy in 50% of culture confirmed TB cases and 35% of all confirmed and unconfirmed cases, with a specificity of 85%.
Developed in tertiary research-experienced health facilities, the PAANTHER score could enable standardized treatment decision in HIV-infected children with presumptive TB, and could be recommended for extensive use in secondary and primary healthcare settings where most of these children are seeking care. However, external validation studies are now needed to assess the predictive performance of the PAANTHER diagnostic score on independent datasets.
The PAANTHER TB treatment decision algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. Validation of the algorithm will be performed by evaluating the safety of withholding TB treatment in children not initiated on treatment as per the PAANTHER TB treatment decision algorithm. The safety of this strategy will be carefully assessed through review of safety reports every 4 to 6 months during study conduct by the safety sub-committee of the SAB.
Occurrence of algorithm failures in terms of missed TB cases (TB cases subsequently detected among untreated cases, i.e. false negatives) and cases with unlikely TB among those initiated on TB treatment as per the algorithm (cases not secondarily validated as confirmed or unconfirmed TB cases by the expert committee, i.e. false positives) will enable to estimate the negative and positive predictive values of the algorithm.
A centralized international Expert Committee will clinically review and validate TB diagnosis in children. This will enable assessment of the added value of new markers (MLR and CRP) and, if need be, to propose a new version of the score based on an optimised predicted probability.
The TB-Speed HIV study will be implemented in 7 tertiary healthcare level hospitals in capital cities of Côte d'Ivoire, Uganda, Mozambique, and Zambia. A total of 550 HIV-infected children (aged < 15 years) with clinically suspected TB (presumptive TB) will be enrolled, using standard entry criteria. The inclusion period will last until all sites have reached the expected number of children enrolled.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Abidjan, Costa do Marfim
- Cocody University Teaching Hospital
-
Abidjan, Costa do Marfim
- Treichville University Teaching Hospital
-
-
-
-
-
Maputo, Moçambique
- José Macamo General Hospital
-
Maputo, Moçambique
- Maputo Central Hospital
-
-
-
-
-
Mbarara, Uganda
- Mbarara Regional Hospital
-
-
-
-
-
Lusaka, Zâmbia
- Lusaka University Teaching Hospital
-
Ndola, Zâmbia
- Arthur Davidson Children Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Children aged 1 month to 14 years
-
Documented HIV-infection (i.e., confirmed before entry into the study)
-
Presumptive TB based on at least one criteria among the following:
- Persistent cough for more than 2 weeks
- Persistent fever for more than 2 weeks
- Recent failure to thrive (documented clear deviation from a previous growth trajectory in the last 3 months or Z score weight/age < 2)
- Failure of broad spectrum antibiotics for treatment of pneumonia
- Suggestive CXR features
OR
History of contact with a TB case and any of the symptoms listed under point 3 with a shorter duration (< 2 weeks)
-
Informed consent signed by parent/guardian
Exclusion Criteria:
Ongoing TB treatment or history of intake of anti-TB drugs in the last 3 months (isoniazid alone or rifampin/isoniazid for preventive therapy is not an exclusion criteria)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: HIV-infected children with presumptive TB
Recruitment will be performed at entry in HIV outpatient/inpatient centres of participating hospitals, as well as during the follow up of HIV-infected children on ART. Children will be first pre-screened for TB by attending clinicians and nurses in the context of routine care based on WHO criteria, i.e. with any one of the following symptoms: poor weight gain, fever, current cough and contact with a TB case. If not routinely performed, this pre-screening step will be reinforced and a screening logbook will be set up (if not already in place) to collect aggregated data on the eligibility criteria assessment process. Children pre-screened positive for TB will be further subjected to the study selection criteria by the study nurses. |
The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:
A score of >100 is highly predictive of TB. In children with a score >100, anti-TB treatment will be initiated immediately. In children with a score of <100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of missed TB cases
Prazo: 6 months
|
Proportion of missed TB cases (false negative cases) in children not initiated on treatment as per the PAANTHER TB treatment decision algorithm |
6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Viabilidade do algoritmo de decisão de tratamento de TB PAANTHER (b): Tempo para decisão final de tratamento de TB
Prazo: 6 meses
|
6 meses
|
|
|
Incidência de mortalidade
Prazo: 6 meses
|
6 meses
|
|
|
Tempo para o início da TARV em crianças virgens de TARV
Prazo: 6 meses
|
6 meses
|
|
|
Resultados do tratamento de TB (b): resolução dos sintomas de TB em crianças em tratamento de TB
Prazo: 6 meses
|
6 meses
|
|
|
Feasibility of the PAANTHER TB treatment decision algorithm (a): Proportion of children with presumptive TB having completed the algorithm.
Prazo: 6 months
|
The algorithm will be considered completed if a decision to initiate TB treatment has been taken at any step of the algorithm or if TB has been excluded after systematic evaluation, and all steps planned in the algorithm have been implemented. |
6 months
|
|
Proportion of HIV-infected children with unlikely TB among those initiated on treatment as per the PAANTHER TB treatment decision algorithm
Prazo: 6 months
|
Proportion of cases considered as unlikely TB by the Expert Committee in those initiated on treatment as per the PAANTHER TB treatment decision algorithm (false positive) |
6 months
|
|
Incidence of morbidity
Prazo: 6 months
|
Incidence of morbidity defined as drug-induced toxicity (ART and TB treatment-related), opportunistic infections, and IRIS, with or without TB treatment |
6 months
|
|
CD4 (absolute count and %) gain
Prazo: 6 months
|
Immunologic evolution at 6 months after enrolment defined as CD4 cells gain (absolute count and %) |
6 months
|
|
TB treatment outcomes (a): Weight gain at 6 months (absolute value and percentage of body weight)
Prazo: 6 months
|
TB treatment outcome in HIV-infected children initiated on treatment as per the PAANTHER TB treatment decision algorithm defined by weight gain at 6 months (absolute value and percentage of body weight) |
6 months
|
|
Feasibility of IPT initiation (a): Time to IPT initiation
Prazo: 6 months
|
Time to Isoniazid Preventive Therapy (IPT) initiation in HIV-infected children not initiated on treatment as per the PAANTHER TB treatment decision algorithm (a) |
6 months
|
|
Feasibility of IPT initiation (b): Proportion of children initiated on IPT
Prazo: 6 months
|
Proportion of children initiated on IPT in HIV-infected children not initiated on treatment as per the PAANTHER TB treatment decision algorithm (b) |
6 months
|
|
Performance of the Monocyte-to-Lymphocyte Ratio and the C-reactive protein and their potential added value in the PAANTHER score and algorithm to detect TB
Prazo: 6 months
|
Discrimination (area under the receiver-operating-characteristic curves [AUROC]) and calibration measures of the PAANTHER prediction model including or not MLR and CRP, against the TB composite reference standard as defined by the Expert Committee |
6 months
|
|
Proportion of NPAs (or sputum) and stool samples with mycobacterium tuberculosis (MTB) detected using Ultra
Prazo: 6 months
|
Diagnostic performance of Ultra performed on one NPA and one stool sample against mycobacterial culture performed on standard samples in HIV-infected children |
6 months
|
|
Proportion of children with NPA and stool samples collected as per study protocol
Prazo: 6 months
|
Feasibility of NPA and stool samples collection in HIV-infected children defined as the proportion of children with NPA and stool samples collected as per study protocol |
6 months
|
|
Proportion of NPA-related adverse events (AEs)
Prazo: 6 months
|
Safety of NPA collection defined as proportion of AEs (vomiting, nose bleeding, low oxygen saturation, respiratory distress) occurring during NPA |
6 months
|
|
Discomfort/pain/distress experienced by the child during NPA as assessed by the child
Prazo: Within 3 days of inclusion
|
Tolerability of NPA collection defined as discomfort/pain/distress experienced by the child during NPA, as assessed by the child using the Wong-Baker face scale (in a subset of children). Scale range: 0 (no hurt) - 5 (hurts worst) |
Within 3 days of inclusion
|
|
Discomfort/pain/distress experienced by the child during NPA as assessed by the parents
Prazo: Within 3 days of inclusion
|
Tolerability of NPA collection defined as discomfort/pain/distress experienced by the child during NPA, as assessed by the parents using the visual analog scale (in a subset of children). Scale range: 0 (no pain) - 10 (pain as bad as it could possibly be) |
Within 3 days of inclusion
|
|
Discomfort/pain/distress experienced by the child during NPA as assessed by the nurse
Prazo: Within 3 days of inclusion
|
Tolerability of NPA collection defined as discomfort/pain/distress experienced by the child during NPA, as assessed by the nurses using the "Face Legs Activity Cry Consolability" behavioral pain scale (in a subset of children). Total score range: 0 (relaxed and comfortable) - 10 (severe discomfort/pain). Each item of the FLACC scale - Face, Legs, Activity, Cry, Consolability - has 3 possible quotes: 0 or 1 or 2, with a precise description provided to help with the rating. The total score is obtained by adding individual item scores. |
Within 3 days of inclusion
|
|
Sensitivity
Prazo: 6 months
|
false negative rate, i.e. negative predictive value, and corresponding sensitivity of the PAANTHER algorithm in the different subgroups in terms of age, CD4 counts, nutritional statuses, and timings of ART initiation (on/off ART) |
6 months
|
|
Positivity
Prazo: 6 months
|
false positiverate, i.e. Positive predictive value, and corresponding positivity of the PAANTHER algorithm in the different subgroups in terms of age, CD4 counts, nutritional statuses, and timings of ART initiation (on/off ART) |
6 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incremental cost-effectiveness ratio (ICER)
Prazo: 33 months
|
Incremental cost-effectiveness ratio (ICER) |
33 months
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Olivier Marcy, MD, PhD, University of Bordeaux, France
- Investigador principal: Eric Wobudeya, MD, PhD, MU-JHU Care Ltd, Kampala, Uganda
- Investigador principal: Maryline Bonnet, MD, PhD, Institut de Recherche pour le Développemnt (IRD) Montpellier, France
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- C18-27
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .